You just read:

Janssen Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients with Multiple Myeloma Who Are Transplant Ineligible

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Jun 27, 2019, 14:27 ET